Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Almonertinib Plus Metronomic Oral Vinorelbine Beyond Limited Progression on Third-generation TKI in EGFR-mutant Advanced NSCLC,an Observational Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05663177
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:51.459400+00:00
Published At
2022-12-23T00:00:00+00:00
Record Updated At
2022-12-23
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["EGFR", "NSCLC", "Third-generation TKI"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-12-23"
protocolSection.identificationModule.nctId
"NCT05663177"
protocolSection.identificationModule.officialTitle
"Almonertinib Plus Metronomic Oral Vinorelbine Beyond Limited Progression on Third-generation TKI in EGFR-mutant Advanced NSCLC\uff0can Observational Study"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
[]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • EGFR (protocolSection.conditionsModule.conditions)
  • NSCLC (protocolSection.conditionsModule.conditions)
  • Third-generation TKI (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.